Literature DB >> 3066813

Insulin and C-peptide in ascitic fluid and plasma and their relative responses to glucagon in patients with cirrhosis.

S Akgün1, A Samanta, N H Ertel.   

Abstract

Insulin (IRI) and C-peptide dynamics were studied after iv glucagon in 5 nondiabetic patients with ascites due to cirrhosis of the liver. Plasma and ascitic fluid samples for glucose, IRI and C-peptide determinations were obtained before and 6, 10, 15, 20 and 30 min after glucagon injection. Ascitic fluid volumes, estimated by dilution of ip injected PAH, were 6.2 to 20.5 L. The mean fasting plasma glucose [88 +/- 6.7 mg/dl (SE)] and C-peptide (1.40 +/- 0.42 ng/ml) levels were normal; mean plasma insulin was increased (17.4 +/- 3.0 microU/ml). After glucagon injection, there was a subnormal rise in plasma glucose (PG) compared to 5 mild diabetic patients without liver disease (8.4 +/- 3.5 vs 76 +/- 7.4 mg/dl). The plasma C-peptide rise was less than that of plasma IRI (54% vs 192%). The mean basal ascitic fluid concentration of glucose was 86 +/- 9.4 mg/dl, IRI 13.2 +/- 2.9 microU/ml and C-peptide 3.09 +/- 0.49 ng/ml. Total calculated basal ascitic fluid contents of glucose was 5.2-23.3 g, IRI 47, 120-290,000 microU and C-peptide 15,750-66,420 ng. These were 3-10 times the quantity of these substances circulating in the plasma volume. After glucagon injection, there was no significant increase in ascitic fluid glucose or IRI, but there was a 43% increase in C-peptide concentration at 10 min. In ascitic fluid, the molar concentration of IRI was lower and C-peptide higher than plasma, resulting in a C-peptide: IRI molar ratio of 11.31, markedly higher than the published normal plasma ratio of 4.63.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3066813     DOI: 10.1007/BF03350226

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  14 in total

1.  Estimation of ascitic fluid volumes.

Authors:  L BAKER; R C PUESTOW; S KRUGER; J H LAST
Journal:  J Lab Clin Med       Date:  1952-01

2.  [Comparative study of glucose and insulin levels in peripheral venous blood and ascitic fluid in the patient with alcoholic cirrhosis during induced oral hyperglycemia].

Authors:  B Hillemand; J P Joly; P Brunelle; L Legueult; P Huet
Journal:  Ann Med Interne (Paris)       Date:  1974-04

3.  Potassium depletion in hepatic cirrhosis. A reversible cause of impaired growth-hormone and insulin response to stimulation.

Authors:  S Podolsky; H J Zimmerman; B A Burrows; J A Cardarelli; C G Pattavina
Journal:  N Engl J Med       Date:  1973-03-29       Impact factor: 91.245

4.  Glucose intolerance and insulin resistance in patients with liver disease.

Authors:  J R Collins; O B Crofford
Journal:  Arch Intern Med       Date:  1969-08

5.  The presence of glucagon in ascitic fluid in cirrhotic patients.

Authors:  U M Kabadi; M S Uddinn; A B Eisenstein
Journal:  J Endocrinol Invest       Date:  1983-06       Impact factor: 4.256

6.  [Glucose and insulin in the blood and ascitic fluid after oral administration of glucose in hepatic cirrhosis].

Authors:  A V Greco; A G Rebuzzi; L Altomonte; R Manna; G Ghirlanda
Journal:  Minerva Dietol Gastroenterol       Date:  1982 Apr-Jun

7.  Plasma concentrations and transperitoneal transport of native insulin and C-peptide in patients on continuous ambulatory peritoneal dialysis.

Authors:  T E Wideröe; L C Smeby; O L Myking
Journal:  Kidney Int       Date:  1984-01       Impact factor: 10.612

8.  Degradation and secretion of insulin in hepatic cirrhosis.

Authors:  Y Iwasaki; A Ohkubo; H Kajinuma; Y Akanuma; K Kosaka
Journal:  J Clin Endocrinol Metab       Date:  1978-10       Impact factor: 5.958

9.  Hyperinsulinism of hepatic cirrhosis: Diminished degradation or hypersecretion?

Authors:  D G Johnson; K G Alberti; O K Faber; C Binder
Journal:  Lancet       Date:  1977-01-01       Impact factor: 79.321

10.  Metabolism of C-peptide in the dog. In vivo demonstration of the absence of hepatic extraction.

Authors:  K Polonsky; J Jaspan; W Pugh; D Cohen; M Schneider; T Schwartz; A R Moossa; H Tager; A H Rubenstein
Journal:  J Clin Invest       Date:  1983-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.